Please provide your email address to receive an email when new articles are posted on . Patients with atopic dermatitis that were resistant to systemic therapies, including dupilumab, were treated ...

Topical ruxolitinib does not carry the same safety profile as oral JAK inhibitors for AD, which may warrant reconsideration of the boxed warning.

Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

High-dose upadacitinib was found to be most effective in improving AD and itch severity, quality of life and AD flares, but was determined to be among the most harmful with regard to adverse events.

Please provide your email address to receive an email when new articles are posted on . Pimecrolimus improved six of seven assessed outcomes. Upadacitinib was among the most effective but also most ...

The National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab (Ebglyss, Almirall) for treating moderate to severe atopic dermatitis in eligible adults and adolescents.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Young children with moderate-to-severe atopic dermatitis (AD) are shorter on average than their peers. Researchers hypothesized that sleep deprivation or long-term exposure to topical or systemic ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test ...

Although previous research has demonstrated the superiority of various herbal medicines over comparator therapies for atopic dermatitis, there are insufficient data to warrant any specific ...